3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Colorectal Neoplasms
39
Pancreatic Neoplasms
19
Stomach Neoplasms
13
Colonic Neoplasms
12
Carcinoma, Non-Small-Cell Lung
11
Adenocarcinoma Of Esophagus
11
Rectal Neoplasms
10
Neoplasm Metastasis
10
Burkitt Lymphoma
10
Neoplasms
9
Esophageal Neoplasms
9
Cholangiocarcinoma
6
Adenocarcinoma
6
Precursor Cell Lymphoblastic Leukemia-Lymphoma
4
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
4
Lung Neoplasms
4
Leukemia, Biphenotypic, Acute
4
Esophageal Squamous Cell Carcinoma
4
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
3
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Ovarian Neoplasms
3
Gallbladder Neoplasms
3
Endometrial Neoplasms
3
Advanced Solid Tumors
3
Triple Negative Breast Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Lymphoma
2
Gastrointestinal Neoplasms
2
Down Syndrome
2
Carcinoma, Renal Cell
2
Interventions
Carboplatin
3
durvalumab
2
Tretinoin
2
Paclitaxel
2
Irinotecan
2
zanidatamab
1
veliparib
1
tucatinib
1
trilaciclib
1
trebananib
1
trastuzumab duocarmazine
1
tegafur-gimeracil-oteracil
1
talazoparib
1
sarilumab
1
pexidartinib
1
pertuzumab
1
pembrolizumab
1
patritumab
1
olaparib
1
niraparib
1
neratinib
1
ganitumab
1
dostarlimab
1
cemiplimab
1
abemaciclib
1
Trastuzumab
1
Surgical Procedures, Operative
1
Standard of Care
1
STA 9090
1
SGN-LIV1A
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Pathologic Complete Response
×
Leucovorin
×
90 days
×
Clear all
NCT07472868
2026-03-16
MEND-IT II
Catharina Ziekenhuis Eindhoven
Phase 3
Not yet recruiting
394 enrolled